On its usage, Dr Reddy said 2-DG is an oral drug that comes in the form of a powder in a sachet and can be dissolved in water. It can be administered only upon prescription and under the supervision of a qualified physician.
Dr Reddy’s Laboratories on Monday announced the commercial launch of its anti-COVID drug 2DG, developed by the Defence Research and Development Organisation (DRDO) and the price of the same is capped at Rs 990 with a discounted rate offered to government institutions
2DG has been found to help speed up recovery and reduce oxygen dependence. Dr Reddy’s has launched the drug in the form of sachets.
“Dr Reddy’s will supply to major government as well as private hospitals across India. In the initial weeks, the Company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India,” Dr. Reddy’s said in a statement.
The company said that it should ideally be prescribed as early as possible by doctors to patients with moderate to severe symptoms of COVID-19 patients for a maximum duration of 10 days.
“The 2DG should not be given to pregnant and lactating women and patients below 18 years,” it added.
Also Read: Shashi Tharoor-Led Parliamentary Panel Summons Google, Facebook Officers Tomorrow
On its usage, Dr Reddy’s said 2-DG is an oral drug that comes in the form of a powder in a sachet and can be dissolved in water. It can be administered only upon prescription and under the supervision of a qualified physician.
The first batch of DRDO’s anti-Covid-19 drug was released on May 17 by Union defence minister Rajnath Singh and health minister Dr Harsh Vardhan, after the Drugs Controller General of India (DCGI) permitted the emergency use authorisation of 2-deoxy-D-glucose (2-DG), anti-viral drug as an adjunct therapy for moderate to severe coronavirus patients.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
